Wolverine Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$227K Buy
+3,644
New +$230K ﹤0.01% 1140
2025
Q4
– Sell
-220
Closed -$10.6K – 1684
2025
Q3
$9.9K Sell
220
-20,220
-99% -$944K ﹤0.01% 1368
2025
Q2
$946K Buy
+20,440
New +$1M 0.01% 735
2024
Q3
– Sell
-4,024
Closed -$189K – 1659
2024
Q2
$167K Buy
+4,024
New +$180K ﹤0.01% 1021
2024
Q1
– Sell
-32,788
Closed -$1.67M – 1686
2023
Q4
$1.68M Sell
32,788
-15,941
-33% -$837K 0.01% 573
2023
Q3
$2.83M Buy
48,729
+5,042
+12% +$309K 0.03% 456
2023
Q2
$2.79M Sell
43,687
-10,265
-19% -$688K 0.03% 423
2023
Q1
$3.74M Buy
53,952
+17,674
+49% +$1.25M 0.04% 387
2022
Q4
$2.61M Buy
+36,278
New +$2.74M 0.03% 507
2019
Q2
– Sell
-3,933
Closed -$187K – 1407
2019
Q1
$187K Sell
3,933
-287,875
-99% -$14.3M ﹤0.01% 1037
2018
Q4
$15.2M Buy
291,808
+74,430
+34% +$4M 0.18% 117
2018
Q3
$13.5M Buy
217,378
+35,014
+19% +$2.08M 0.16% 132
2018
Q2
$10.1M Buy
182,364
+129,681
+246% +$7M 0.13% 153
2018
Q1
$3.33M Buy
+52,683
New +$3.39M 0.04% 362
2016
Q4
– Sell
-2,404
Closed -$129K – 1179
2016
Q3
$129K Buy
+2,404
New +$154K ﹤0.01% 938
2016
Q1
– Sell
-11,204
Closed -$770K – 1242
2015
Q4
$770K Sell
11,204
-6,650
-37% -$439K 0.02% 547
2015
Q3
$1.06M Buy
17,854
+3,600
+25% +$228K 0.02% 489
2015
Q2
$948K Sell
14,254
-5,600
-28% -$369K 0.02% 488
2015
Q1
$1.28M Buy
19,854
+7,192
+57% +$450K 0.03% 390
2014
Q4
$747K Sell
12,662
-2,122
-14% -$120K 0.01% 530
2014
Q3
$756K Buy
14,784
+3,140
+27% +$157K 0.02% 552
2014
Q2
$564K Buy
11,644
+6,144
+112% +$303K 0.01% 560
2014
Q1
$285K Buy
+5,500
New +$293K 0.01% 758
2013
Q4
– Sell
-37,900
Closed -$1.93M – 2704
2013
Q3
$1.75M Buy
37,900
+10,000
+36% +$439K 0.04% 375
2013
Q2
$1.25M Buy
+27,900
New +$1.21M 0.03% 413

Other funds holding BMY

Wolverine Asset Management's BMY Position: Q3 2026 in Review

Wolverine Asset Management opened a new position in Bristol-Myers Squibb (BMY) in Q3 2026: 3,644 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #1140 among its holdings. This is a return to the name: Wolverine Asset Management previously reported a position in BMY as recently as Q3 2025.

Wolverine Asset Management first reported a position in BMY in Q2 2013 and has held it in 25 quarters since. The position peaked at $15.2M in Q4 2018. 2,568 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Wolverine Asset Management held 3,644 shares of Bristol-Myers Squibb worth $227K as of Q3 2026.
  • Bristol-Myers Squibb was a new Wolverine Asset Management position in Q3 2026.
  • Bristol-Myers Squibb made up ﹤0.01% of Wolverine Asset Management's portfolio in Q3 2026, its #1140 holding.
  • Wolverine Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 25 quarters since.
  • Wolverine Asset Management's Bristol-Myers Squibb position peaked at $15.2M in Q4 2018.
  • 2,568 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Wolverine Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.